Karyopharm Therapeutics Inc.
KPTIKaryopharm Therapeutics Inc. in brief
Karyopharm Therapeutics Inc. is a listed company in the Biotechnology industry, based in Newton, Massachusetts, USA. Its market value was $20 M on 30 October 2026, which makes it the 24,359th largest listed company in the world and the 4,160th largest in the USA on this site. In the year to December 2025 it had sales of $146 M and a net loss of $196 M. It employs about 442 people and Richard A. Paulson is its chief executive. Its largest product and service lines by sales in 2025 were License and Other Revenue (21%). Its shares trade under the symbol KPTI (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Karyopharm Therapeutics Inc.
Karyopharm Therapeutics is an Innovation Driven Pharmaceutical company. It is focused on the discovery, development and commercialization of medicines with the goal of improving the lives of patients with cancer and other major diseases. The headquarters is in USA.
Karyopharm Therapeutics Inc. timeline
- 2010
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2013
- 🔔· approximateInitial public offering on Nasdaq
- 2021
- 💰Record revenue of $210 millionFY2021, the highest of the 8 years on record.
Events of Karyopharm Therapeutics Inc. from SEC EDGAR, the company record and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #1,960 (Jan 2020) · #2,060 (Jan 2021) · #3,217 (Jan 2022) · #3,627 (Dec 2022) · #3,584 (Jul 2023) · #3,722 (Jan 2024) · #1,792 (Mar 2026) · #3,763 (Aug 2026) · #4,163 (Oct 2026)
Key ratios
- P/E ratio (TTM)
- n/m (loss)
- Price / sales (TTM)
- 0.1×
- Price / book
- —
- Free cash flow yield
- -377.6%
- Net margin (TTM)
- -153.3%
- Operating margin
- -62.1%
- Return on equity
- —
- Liabilities / assets
- 370.2%
- Net debt
- $-21M
- Revenue growth
- +0.6%
- R&D / revenue
- 86.0%
- Revenue per employee
- $330 K
- Profit per employee
- $-444 K
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $146M | +0.6% | $-91M | $-196M | -134.2% |
| Dec 2024 | $145M | -0.5% | $-119M | $-76M | -52.6% |
| Dec 2023 | $146M | -7.0% | $-130M | $-143M | -98.0% |
| Dec 2022 | $157M | -25.1% | $-142M | $-165M | -105.2% |
| Dec 2021 | $210M | +94.1% | $-98M | $-124M | -59.1% |
| Dec 2020 | $108M | +164.3% | $-172M | $-196M | -181.6% |
| Dec 2019 | $41M | +34.8% | $-189M | $-200M | -488.1% |
| Dec 2018 | $30M | — | $-180M | $-178M | -588.0% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-75M | $0M | $-75M | $-17.93 | — |
| Dec 2024 | $-127M | $0M | $-128M | $-14.00 | — |
| Dec 2023 | $-93M | $0M | $-93M | $-18.79 | — |
| Dec 2022 | $-150M | $0M | $-150M | $-2.02 | — |
| Dec 2021 | $-107M | $0M | $-107M | $-1.65 | — |
| Dec 2020 | $-160M | $0M | $-160M | $-2.72 | — |
| Dec 2019 | $-191M | $0M | $-191M | $-3.22 | — |
| Dec 2018 | $-159M | $2M | $-161M | $-3.14 | — |
Quarterly results
Latest quarter to Jun 2026: revenue $33M (-11.9% on a year earlier), net income $-67M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Jun 2026.
SEC filings
- Nov 5, 20268-KCurrent reportListing notice
- Nov 3, 20268-KCurrent reportMaterial agreement · Bankruptcy · New financial obligation · Regulation FD disclosure · Other events
- Nov 2, 20268-KCurrent reportRegulation FD disclosure
- Oct 22, 20268-KCurrent reportOther events
- Oct 14, 20268-KCurrent reportOther events
- Sep 18, 20268-KCurrent reportBylaws amended
- Sep 11, 20268-KCurrent reportMaterial agreement · Unregistered share sale · Other events
- Aug 31, 20268-KCurrent reportOther events
- Aug 13, 202610-QQuarterly report · period to Jun 2026
- Aug 13, 20268-KCurrent reportResults of operations
- Jul 31, 20268-KCurrent reportOther events
- Jul 17, 20268-KCurrent reportDirectors or officers changed
Official filings of Karyopharm Therapeutics Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $146 M
- Operating income
- $-91 M
- Net income
- $-196 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $108 M
- Total liabilities
- $401 M
- Total equity
- $-293 M
As of December-2025
Top 92 institutional investors in Karyopharm Therapeutics Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Adage Capital Partners GP, L.L.C. | 1,997,692 | +476,370 (+31.31%) | 8.81% | $2 M | Nov 16, 2026 |
| 2 | BlackRock, Inc. | 1,521,918 | +103,119 (+7.27%) | 6.71% | $2 M | Nov 13, 2026 |
| 3 | Acorn Capital Advisors, LLC | 1,222,019 | -296,094 (-19.50%) | 5.39% | $1 M | Nov 16, 2026 |
| 4 | Catalio Capital Management, LP | 976,191 | +35,336 (+3.76%) | 4.30% | $1 M | Nov 16, 2026 |
| 5 | UBS Group AG | 963,891 | +610,346 (+172.64%) | 4.25% | $1 M | Nov 10, 2026 |
| 6 | Vanguard Capital Management LLC | 940,813 | -18,166 (-1.89%) | 4.15% | $1 M | Nov 13, 2026 |
| 7 | AQR Capital Management LLC | 931,658 | New | 4.11% | $1 M | Nov 16, 2026 |
| 8 | Avidity Partners Management LP | 884,900 | -39,587 (-4.28%) | 3.90% | $1 M | Nov 16, 2026 |
| 9 | Acadian Asset Management LLC | 617,904 | +318,907 (+106.66%) | 2.72% | $1 M | Nov 9, 2026 |
| 10 | Strs Ohio | 542,500 | New | 2.39% | $1 M | Oct 30, 2026 |
| 11 | Geode Capital Management, LLC | 458,521 | -72,710 (-13.69%) | 2.02% | $1 M | Nov 6, 2026 |
| 12 | Morgan Stanley | 385,745 | +183,239 (+90.49%) | 1.70% | $0 M | Nov 13, 2026 |
| 13 | State Street Corp | 369,341 | +43,350 (+13.30%) | 1.63% | $0 M | Nov 12, 2026 |
| 14 | Brevan Howard Capital Management LP | 352,637 | +42,820 (+13.82%) | 1.55% | $0 M | Nov 16, 2026 |
| 15 | Royal Bank Of Canada | 310,728 | +250,298 (+414.19%) | 1.37% | $0 M | Nov 16, 2026 |
| 16 | Davidson Kempner Capital Management LP | 300,000 | 0 (0.00%) | 1.32% | $0 M | Nov 16, 2026 |
| 17 | Bank Of America Corp /de/ | 278,982 | +229,058 (+458.81%) | 1.23% | $0 M | Nov 16, 2026 |
| 18 | Two Sigma Investments, LP | 273,870 | -421,394 (-60.61%) | 1.21% | $0 M | Nov 16, 2026 |
| 19 | Context Capital Management, LLC | 263,696 | New | 1.16% | $0 M | Nov 4, 2026 |
| 20 | Goldman Sachs Group Inc | 256,190 | -1,168,468 (-82.02%) | 1.13% | $0 M | Nov 16, 2026 |
| 21 | Jpmorgan Chase & Co | 250,611 | +43,002 (+20.71%) | 1.10% | $0 M | Nov 12, 2026 |
| 22 | FMR LLC | 240,312 | +231,376 (+2589.26%) | 1.06% | $0 M | Nov 10, 2026 |
| 23 | Jane Street Group, LLC | 195,300 | +162,127 (+488.73%) | 0.86% | $0 M | Nov 12, 2026 |
| 24 | Susquehanna International Group, LLP | 191,231 | New | 0.84% | $0 M | Nov 16, 2026 |
| 25 | Caption Management, LLC | 185,745 | New | 0.82% | $0 M | Nov 16, 2026 |
Show all 92: investors 26 to 92
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Prudential Financial Inc | 172,610 | New | 0.76% | $0 M | Nov 16, 2026 |
| 27 | Northern Trust Corp | 159,937 | -69 (-0.04%) | 0.71% | $0 M | Nov 16, 2026 |
| 28 | Citadel Advisors LLC | 146,782 | +94,713 (+181.90%) | 0.65% | $0 M | Nov 16, 2026 |
| 29 | Invesco Ltd. | 136,524 | +46,220 (+51.18%) | 0.60% | $0 M | Nov 12, 2026 |
| 30 | Vanguard Portfolio Management LLC | 135,902 | +1,084 (+0.80%) | 0.60% | $0 M | Nov 13, 2026 |
| 31 | Boxer Capital Management, LLC | 127,536 | -175,000 (-57.84%) | 0.56% | $0 M | Nov 16, 2026 |
| 32 | Vanguard Fiduciary Trust Co | 114,068 | -31,333 (-21.55%) | 0.50% | $0 M | Nov 13, 2026 |
| 33 | Virtu Financial LLC | 110,484 | +99,756 (+929.87%) | 0.49% | $0 M | Nov 17, 2026 |
| 34 | D. E. Shaw & Co., Inc. | 95,740 | New | 0.42% | $0 M | Nov 16, 2026 |
| 35 | Quadrature Capital Ltd | 87,086 | +76,790 (+745.82%) | 0.38% | $0 M | Nov 13, 2026 |
| 36 | Panagora Asset Management Inc | 81,102 | New | 0.36% | $0 M | Nov 12, 2026 |
| 37 | BNP Paribas Financial Markets | 73,605 | -114,433 (-60.86%) | 0.32% | $0 M | Nov 12, 2026 |
| 38 | BML Capital Management, LLC | 71,839 | New | 0.32% | $0 M | Nov 6, 2026 |
| 39 | Bridgeway Capital Management, LLC | 71,483 | -390 (-0.54%) | 0.32% | $0 M | Nov 16, 2026 |
| 40 | Simplex Trading, LLC | 69,837 | +45,751 (+189.95%) | 0.31% | $0 M | Nov 4, 2026 |
| 41 | Nuveen, LLC | 65,578 | +27,710 (+73.18%) | 0.29% | $0 M | Nov 10, 2026 |
| 42 | Bank of New York Mellon Corp | 57,262 | 0 (0.00%) | 0.25% | $0 M | Nov 5, 2026 |
| 43 | Group One Trading LLC | 51,174 | New | 0.23% | $0 M | Nov 10, 2026 |
| 44 | Charles Schwab Investment Management Inc | 48,520 | -13,423 (-21.67%) | 0.21% | $0 M | Nov 16, 2026 |
| 45 | Citigroup Inc | 47,191 | +9,274 (+24.46%) | 0.21% | $0 M | Nov 4, 2026 |
| 46 | Millennium Management LLC | 42,888 | -262,788 (-85.97%) | 0.19% | $0 M | Nov 16, 2026 |
| 47 | Marshall Wace, LLP | 39,400 | -89,051 (-69.33%) | 0.17% | $0 M | Nov 13, 2026 |
| 48 | Intellus Advisors LLC | 38,232 | New | 0.17% | $0 M | Nov 13, 2026 |
| 49 | China Universal Asset Management Co., Ltd. | 36,000 | +11,000 (+44.00%) | 0.16% | $0 M | Oct 28, 2026 |
| 50 | Silverback Asset Management LLC | 35,000 | +5,000 (+16.67%) | 0.15% | $0 M | Nov 16, 2026 |
| 51 | Nomura Asset Management International Inc. | 33,333 | 0 (0.00%) | 0.15% | $0 M | Nov 16, 2026 |
| 52 | Rhumbline Advisers | 30,772 | +7,305 (+31.13%) | 0.14% | $0 M | Nov 10, 2026 |
| 53 | Barclays PLC | 28,739 | -137,165 (-82.68%) | 0.13% | $0 M | Nov 6, 2026 |
| 54 | Price T Rowe Associates Inc /MD/ | 27,225 | 0 (0.00%) | 0.12% | $0 M | Nov 16, 2026 |
| 55 | Empowered Funds, LLC | 21,610 | New | 0.10% | $0 M | Nov 13, 2026 |
| 56 | SEI Investments Co | 21,436 | +6,353 (+42.12%) | 0.09% | $0 M | Nov 10, 2026 |
| 57 | Toronto Dominion Bank | 20,000 | -10,930 (-35.34%) | 0.09% | $0 M | Nov 16, 2026 |
| 58 | Deutsche Bank AG\ | 17,029 | -2,396 (-12.33%) | 0.08% | $0 M | Nov 6, 2026 |
| 59 | StoneX Group Inc. | 17,019 | New | 0.07% | $0 M | Nov 3, 2026 |
| 60 | HSBC Holdings PLC | 13,750 | 0 (0.00%) | 0.06% | $0 M | Nov 16, 2026 |
| 61 | MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | 9,640 | +469 (+5.11%) | 0.04% | $0 M | Nov 16, 2026 |
| 62 | Vanguard Global Advisers, LLC | 8,244 | +37 (+0.45%) | 0.04% | $0 M | Nov 13, 2026 |
| 63 | Russell Investments Group, Ltd. | 6,789 | +5,197 (+326.44%) | 0.03% | $0 M | Nov 6, 2026 |
| 64 | Police & Firemen's Retirement System of New Jersey | 5,874 | 0 (0.00%) | 0.03% | $0 M | Nov 9, 2026 |
| 65 | TD Waterhouse Canada Inc. | 5,707 | 0 (0.00%) | 0.03% | $0 M | Oct 16, 2026 |
| 66 | New York State Common Retirement Fund | 5,600 | 0 (0.00%) | 0.02% | $0 M | Nov 17, 2026 |
| 67 | Tower Research Capital LLC (TRC) | 4,607 | +3,348 (+265.93%) | 0.02% | $0 M | Nov 16, 2026 |
| 68 | Wells Fargo & Company/mn | 4,196 | -12,707 (-75.18%) | 0.02% | $0 M | Nov 16, 2026 |
| 69 | PNC Financial Services Group, Inc. | 3,974 | New | 0.02% | $0 M | Nov 6, 2026 |
| 70 | Arax Advisory Partners | 2,451 | New | 0.01% | $0 M | Nov 12, 2026 |
| 71 | Global Retirement Partners, LLC | 2,155 | New | 0.01% | $0 M | Nov 10, 2026 |
| 72 | Legal & General Group Plc | 1,935 | 0 (0.00%) | 0.01% | $0 M | Nov 16, 2026 |
| 73 | Ameritas Investment Partners, Inc. | 1,808 | 0 (0.00%) | 0.01% | $0 M | Nov 13, 2026 |
| 74 | Harbour Investments, Inc. | 1,285 | +1,000 (+350.88%) | 0.01% | $0 M | Nov 9, 2026 |
| 75 | GAMMA Investing LLC | 865 | New | 0.00% | $0 M | Oct 8, 2026 |
| 76 | Owl Creek Wealth Partners LLC | 685 | New | 0.00% | $0 M | Oct 20, 2026 |
| 77 | Osaic Holdings, Inc. | 402 | 0 (0.00%) | 0.00% | $0 M | Nov 12, 2026 |
| 78 | Sterling Capital Management LLC | 340 | -12 (-3.41%) | 0.00% | $0 M | Oct 22, 2026 |
| 79 | Huntington National Bank | 278 | New | 0.00% | $0 M | Nov 10, 2026 |
| 80 | California State Teachers Retirement System | 274 | 0 (0.00%) | 0.00% | $0 M | Nov 13, 2026 |
| 81 | Caitong International Asset Management Co., Ltd | 249 | +235 (+1678.57%) | 0.00% | $0 M | Oct 29, 2026 |
| 82 | Cantor Fitzgerald, L. P. | 173 | New | 0.00% | $0 M | Nov 16, 2026 |
| 83 | Quent Capital, LLC | 166 | 0 (0.00%) | 0.00% | $0 M | Nov 13, 2026 |
| 84 | Allworth Financial LP | 115 | +89 (+342.31%) | 0.00% | $0 M | Nov 17, 2026 |
| 85 | MB, Levis & Associates, LLC | 100 | 0 (0.00%) | 0.00% | $0 M | Oct 16, 2026 |
| 86 | SBI Securities Co., Ltd. | 69 | +2 (+2.99%) | 0.00% | $0 M | Oct 22, 2026 |
| 87 | Activest Wealth Management | 66 | 0 (0.00%) | 0.00% | $0 M | Oct 15, 2026 |
| 88 | Farther Finance Advisors, LLC | 66 | New | 0.00% | $0 M | Oct 8, 2026 |
| 89 | EverSource Wealth Advisors, LLC | 15 | New | 0.00% | $0 M | Nov 4, 2026 |
| 90 | IFP Advisors, Inc | 7 | New | 0.00% | $0 M | Oct 16, 2026 |
| 91 | West Branch Capital LLC | 3 | 0 (0.00%) | 0.00% | $0 M | Oct 20, 2026 |
| 92 | PlanVest Financial, Inc | 1 | 0 (0.00%) | 0.00% | $0 M | Nov 9, 2026 |
Mutual funds holding Karyopharm Therapeutics Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 677,729 | $7 M | 3.0% | <0.01% | +33% | Jun 30, 2026 |
| 🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors | 490,317 | $5 M | 2.2% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 T. Rowe Price Small-Cap Value Fund, Inc.T. Rowe Price Associates, Inc. | 435,070 | $4 M | 1.9% | 0.04% | −50% | Jun 30, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 263,084 | $3 M | 1.2% | <0.01% | +22% | Jun 30, 2026 |
| 🇺🇸 T. Rowe Price Small-Cap Value Fund, Inc.T. Rowe Price Associates, Inc. | 447,624 | $2 M | — | 0.02% | no change | Jun 30, 2026 |
| 🇺🇸 iShares Russell 2000 Value ETFBlackRock Fund Advisors | 153,539 | $2 M | 0.68% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 94,581 | $1 M | 0.42% | <0.01% | +5.0% | May 31, 2026 |
| 🇺🇸 iShares Russell 2000 Growth ETFBlackRock Fund Advisors | 81,441 | $1 M | 0.36% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors | 66,938 | $1 M | 0.30% | 0.04% | +57% | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC | 216,009 | $0 M | 0.95% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC | 37,232 | $0 M | 0.16% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Nomura Healthcare FundDelaware Management Company | 33,333 | $0 M | 0.15% | 0.04% | no change | Jun 30, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 34,152 | $0 M | 0.15% | <0.01% | +13% | May 31, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 28,115 | $0 M | 0.12% | <0.01% | +18% | May 31, 2026 |
| 🇺🇸 Fidelity Small Cap Value Index FundFidelity Management & Research Company LLC | 23,571 | $0 M | 0.10% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 Ultra-Small Company Market FundBridgeway Capital Management, LLC | 22,000 | $0 M | 0.10% | 0.15% | no change | Jun 30, 2026 |
| 🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC | 21,052 | $0 M | 0.09% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation | 14,900 | $0 M | 0.07% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 T. Rowe Price Extended Equity Market Index FundT. Rowe Price Associates, Inc. | 10,886 | $0 M | 0.05% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc. | 10,410 | $0 M | 0.05% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Diversified Equity Alpha Master PortfolioBlackRock Fund Advisors | 10,259 | $0 M | 0.05% | <0.01% | +595% | Jun 30, 2026 |
| 🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc. | 10,021 | $0 M | 0.04% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc. | 48,520 | $0 M | 0.21% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 10,033 | $0 M | 0.04% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc. | 8,145 | $0 M | 0.04% | <0.01% | +48% | Jun 30, 2026 |
| 🇺🇸 VIP Disciplined Small Cap PortfolioFidelity Management & Research Company LLC | 8,052 | $0 M | 0.04% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 MetLife Russell 2000 Index PortfolioBrighthouse Investment Advisers, LLC | 6,815 | $0 M | 0.03% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc. | 6,800 | $0 M | 0.03% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Invesco RAFI US 1500 Small-Mid ETFInvesco Capital Management LLC | 32,185 | $0 M | 0.14% | <0.01% | +92% | Jul 31, 2026 |
| 🇺🇸 Tiff Multi-Asset FundTIFF Advisory Services, LLC | 5,758 | $0 M | 0.03% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC | 5,505 | $0 M | 0.02% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC | 26,676 | $0 M | 0.12% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC | 4,517 | $0 M | 0.02% | 0.02% | +50% | Jun 30, 2026 |
| 🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC | 4,357 | $0 M | 0.02% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Small Cap Index TrustJohn Hancock Variable Trust Advisers LLC | 4,315 | $0 M | 0.02% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS | 4,306 | $0 M | 0.02% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC | 3,530 | $0 M | 0.02% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC | 3,530 | $0 M | 0.02% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Blackstone Alternative Multi-Strategy FundBlackstone Alternative Investment Advisors LLC | 3,167 | $0 M | 0.01% | <0.01% | +116% | Jun 30, 2026 |
| 🇺🇸 BlackRock Advantage SMID Cap V.I. FundBlackRock Advisors, LLC | 3,139 | $0 M | 0.01% | 0.02% | new | Jun 30, 2026 |
| 🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc. | 3,116 | $0 M | 0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc. | 3,002 | $0 M | 0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Growth Index FundFidelity Management & Research Company LLC | 2,805 | $0 M | 0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC | 2,638 | $0 M | 0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc. | 13,400 | $0 M | 0.06% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 1290 VT Small Cap Value PortfolioEquitable Investment Management Group, LLC | 2,564 | $0 M | 0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Voya RussellTM Small Cap Index PortfolioVoya Investments, LLC | 2,459 | $0 M | 0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC | 9,500 | $0 M | 0.04% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 CVT Russell 2000 Small Cap Index PortfolioCalvert Research and Management | 1,808 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Venerable Small Cap Index FundVenerable Investment Advisers, LLC | 1,592 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Voya VACS Index Series SC PortfolioVoya Investments, LLC | 1,464 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 PD Small-Cap Value Index PortfolioPacific Life Fund Advisors LLC | 1,138 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Strategic Equity Allocation TrustJohn Hancock Variable Trust Advisers LLC | 942 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC | 4,151 | $0 M | 0.02% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 EQ/Franklin Small Cap Value Managed Volatility PortfolioEquitable Investment Management Group, LLC | 676 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Small-Cap Equity PortfolioPacific Life Fund Advisors LLC | 645 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 State Street Total Return V.I.S. FundSSGA Funds Management, Inc. | 503 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 SA Small Cap Index PortfolioSunAmerica Asset Management, LLC | 2,332 | $0 M | 0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc. | 2,258 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC | 407 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Nationwide Small Cap Index FundNATIONWIDE FUND ADVISORS | 1,734 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Nationwide Fundamental All Cap Equity PortfolioNATIONWIDE FUND ADVISORS | 1,561 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 SmallCap Value Fund IIPrincipal Global Investors, LLC | 1,383 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 SmallCap Growth Fund IPrincipal Global Investors, LLC | 226 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Knights of Columbus U.S. ALL CAP INDEX FUNDKnights of Columbus Asset Advisors LLC | 126 | $0 M | <0.01% | <0.01% | +30% | Jul 31, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 65 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Karyopharm Therapeutics Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Kristin AbateChief Accounting Officer | Sell | -4,788 | $0.344 | — | 18,616 | Form 4 |
| filed | Kristin AbateChief Accounting Officer | Sell | -378 | $1.190 | $450 | 23,404 | Form 4 |
| filed | Kristin AbateChief Accounting Officer | Sell | -19 | $2.020 | $38 | 23,782 | Form 4 |
| filed | Stuart PoultonEVP, Chief Development Officer | Sell | -189 | $7.100 | $1 K | 94,632 | Form 4 |
| filed | Barry E. GreeneDirector | Grant or award | +15,508 | — | — | 16,415 | Form 4 |
| filed | Deepika PakianathanDirector | Grant or award | +15,508 | — | — | 15,508 | Form 4 |
| filed | Chen SchorDirector | Grant or award | +15,508 | — | — | 15,508 | Form 4 |
| filed | Zhen SuDirector | Grant or award | +15,508 | — | — | 15,508 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Karyopharm Therapeutics Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Bankruptcy filing: (8-K)
Trading halts
- 2026-11-02 12:07 UTC, code T3, resumed 12:40 UTC
- 2026-07-30 20:01 UTC, code T3, resumed 20:35 UTC
- 2026-03-24 10:56 UTC, code T3, resumed 11:30 UTC
- 2025-08-15 16:32 UTC, code LUDP, resumed 16:37 UTC
- 2025-02-26 00:50 UTC, code T3, resumed 14:00 UTC
Fails to deliver
- : 362,517 shares at $0.88
- : 766,706 shares at $0.83
- : 2,661 shares at $0.48
- : 17,824 shares at $0.48
- : 126,452 shares at $0.52
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Karyopharm Therapeutics Inc. scorecard#
Passes 5 of the 18 checks that could be worked out: strongest in growth (2 of 6), weakest in valuation (1 of 4). Fiscal year 2025; market cap of Oct 30, 2026.
Valuation1 of 4
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✗Price to book below its peers' medianNo price to bookShareholders' equity is negative.
- ✓Price to sales below its peers' median0.1×Price to sales 0.1× against Biotechnology's median of 8.7×.
- –Free cash flow yield above 5%No free cash flow yield on file.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth2 of 6
- ✓Revenue grew in the newest year0.6%Revenue up 0.6% in fiscal 2025.
- ✗Revenue up more than 5% a year over three years-2.4%-2.4% a year over the three years to fiscal 2025.
- ✗Faster growth over three years than its peers' median-2.4%-2.4% a year against Biotechnology's median of 12.9% (181 companies).
- ✗Earnings per share grew in the newest year-17.93 vs -14.00Diluted EPS -17.93 in fiscal 2025 against -14.00 the year before (report's currency).
- ✓Net income higher than five years earlier-$196 M-$196 M in fiscal 2025 against -$196 M in 2020.
- ✗Revenue rose in at least four of the last five years2 of 5Revenue rose in 2 of the five years to fiscal 2025.
Profitability1 of 4
- ✗Profitable in the newest year-$196 MNet income -$196 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- ✗Operating margin above its peers' median-62.1%-62.1% against Biotechnology's median of -60.5% (243 companies).
- –Return on equity above 15%No return on equity (equity missing or negative).
- –Return on invested capital above 10%No return on invested capital on file.
- ✓Operating margin wider than three years earlier-62.1%-62.1% in fiscal 2025 against -90.5% in 2022.
Financial health1 of 3
- ✓Short-term assets cover short-term liabilities1.1×Current ratio 1.12 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- ✗Altman Z-score outside the distress zone-23.98Z-score -23.98 (distress zone) for fiscal 2025.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year37.5%Diluted shares up 37.5% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Financial analysis, 2025#
Worked out from Karyopharm Therapeutics Inc.'s statements, beside the median of Biotechnology.
| Ratio | Trend | 2025 | Median of peers |
|---|---|---|---|
| Operating margin | -62.1% | -60.5% | |
| Net margin | -134.2% | -68.9% | |
| Revenue growth, 3 years a year | -2.4% | 12.9% | |
| Revenue growth | 0.6% | 15.8% | |
| Free cash flow margin | -51.6% | -61.5% |
2of 7on the Piotroski tests of financial strength
- Net loss of $196 million, the 14th loss-making year in a row.
- Free cash flow was negative: -$75 million.
- The share count rose 37.5% in the year.
- Shareholders' equity is negative: -$293 million.
Karyopharm Therapeutics Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 | FY 2016to Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | 146+0.6%100% | 145−0.5%100% | 146−7.0%100% | 157−25.1%100% | 210+94.1%100% | 108+164%100% | 41+34.8%100% | 30+1790%100% | 1.6+942%100% | 0.2—100% | |
| Research and development | 126−12.3%86.0% | 143+3.2%98.6% | 139−6.7%95.0% | 149−7.6%94.6% | 161+6.6%76.7% | 151+23.3%140% | 122−24.2%299% | 161+50.4%532% | 107+23.4%6684% | 87—56453% | |
| Selling, general and administrative | 105−8.9%72.0% | 115−12.5%79.5% | 132−9.3%90.3% | 145+1.1%92.6% | 144+13.8%68.6% | 126+19.9%117% | 105+116%258% | 49+96.4%161% | 25—1550% | — | |
| General and administrative | — | — | — | — | — | — | — | 49+96.4%161% | 25+3.9%1550% | 24—15551% | |
| Operating expenses | 237−10.5%162% | 265−4.0%182% | 276−7.9%189% | 299−2.9%191% | 308+10.1%147% | 280+21.6%259% | 230+9.5%563% | 210+59.1%693% | 132+19.2%8233% | 111—72004% | |
| Operating income | −91—−62.1% | −119—−82.2% | −130—−88.7% | −142—−90.5% | −98—−46.8% | −172—−159% | −189—−463% | −180—−593% | −131—−8133% | −111—−71904% | |
| Interest and finance income | 2.8−62.5%1.9% | 7.4−32.4%5.1% | 11+364%7.5% | 2.4+305%1.5% | 0.6−79.4%0.3% | 2.8−48.0%2.6% | 5.4+34.6%13.3% | 4.0+137%13.3% | 1.7+32.2%106% | 1.3—834% | |
| Interest expense and finance costs | 46+22.5%31.4% | 37+57.1%25.8% | 24−4.7%16.3% | 25−4.0%15.9% | 26−4.0%12.4% | 27+73.5%25.1% | 16+528%38.3% | 2.5—8.2% | — | — | |
| Other non-operating income (expense) | −105−344%−72.1% | 43—29.7% | −13—−9.1% | −23—−14.5% | −26—−12.2% | −24—−22.3% | −10−784%−25.1% | 1.5−7.1%5.0% | 1.6+25.0%101% | 1.3—840% | |
| Income before tax | −196—−134% | −76—−52.6% | −143—−97.8% | −165—−105% | −124—−59.0% | −196—−181% | −200—−488% | −178—−588% | −129—−8032% | −109—−71064% | |
| Income tax | 0.0−24.6%0.0% | 0.1−82.4%0.0% | 0.3−12.5%0.2% | 0.4+37.7%0.2% | 0.3−13.3%0.1% | 0.3+673%0.3% | 0.0+53.8%0.1% | 0.0−58.7%0.1% | 0.1−54.7%3.9% | 0.1—90.3% | |
| Net income including minority interests | −196—−134% | −76—−52.6% | −143—−98.0% | −165—−105% | −124—−59.1% | −196—−182% | −200—−488% | −178—−588% | −129—−8036% | −110—−71154% | |
| Net income attributable to shareholders | −196—−134% | −76—−52.6% | −143—−98.0% | −165—−105% | −124—−59.1% | −196—−182% | −200—−488% | −178—−588% | −129—−8036% | −110—−71154% | |
| Earnings per share, basic | -17.93—— | -9.41r-0.63—— | -18.79r-1.25—— | -2.02—— | -1.65—— | -2.72—— | -3.22—— | -3.14—— | -2.81—— | -2.92—— | |
| Earnings per share, diluted | -17.93—— | -14.00r-0.93—— | -18.79r-1.25—— | -2.02—— | -1.65—— | -2.72—— | -3.22—— | -3.14—— | -2.81—— | -2.92—— | |
| Shares, weighted average (basic) | 0.0+34.6%— | 0.0r0.1+6.7%— | 0.0r114−90.7%— | 0.1r82−99.9%— | 75+4.4%— | 72—— | — | — | — | — | |
| Shares, weighted average (diluted) | 0.0+29.3%— | 0.0r0.1+11.0%— | 0.0r114−90.7%— | 0.1r82−99.9%— | 75+4.4%— | 72r0.1+16.3%— | 62r62+109014%— | 0.1r57−99.9%— | 46+22.3%— | 38—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 61−3.1%55.8% | 62+19.6%38.0% | 52r52−61.4%21.7% | 135−29.0%37.7% | 190+122%62.4% | 86−33.3%27.4% | 129+9.2%43.7% | 118+71.1%34.6% | 69+38.9%38.3% | 50—27.5% | |
| Short-term investments | 3.2−93.1%3.0% | 46−66.8%28.1% | 139−2.5%57.9% | 143+274%39.9% | 38−76.6%12.5% | 163+22.7%52.2% | 133−36.7%45.1% | 210+171%61.6% | 77−3.0%43.0% | 80—44.3% | |
| Receivables | 26−14.9%24.1% | 31+14.1%18.7% | 27−42.7%11.2% | 47+109%13.1% | 22+74.7%7.4% | 13+63.8%4.1% | 7.9—2.7% | — | — | — | |
| Inventory | 4.0−14.8%3.7% | 4.7+55.7%2.9% | 3.0−28.0%1.3% | 4.2+2.9%1.2% | 4.1+55.3%1.3% | 2.6+664%0.8% | 0.3—0.1% | — | — | — | |
| Other current assets | 9.2−25.0%8.5% | 12+3.7%7.4% | 12−40.4%4.9% | 20+1197%5.5% | 1.5−83.5%0.5% | 9.3+27.4%3.0% | 7.3+13.7%2.5% | 6.4+266%1.9% | 1.8−15.8%1.0% | 2.1—1.2% | |
| Current assets | 103−34.1%95.1% | 156r156−33.1%95.2% | 234−33.2%97.3% | 350+27.1%97.8% | 276−0.3%90.3% | 277−0.7%88.3% | 279−16.7%94.4% | 335+125%98.1% | 148+12.8%82.3% | 132—73.0% | |
| Property, plant and equipment | 0.1−74.0%0.1% | 0.4−34.0%0.2% | 0.6−46.8%0.3% | 1.1−30.6%0.3% | 1.6−26.0%0.5% | 2.2−27.2%0.7% | 3.0−21.1%1.0% | 3.9+76.8%1.1% | 2.2−23.0%1.2% | 2.8—1.6% | |
| Right-of-use (leased) assets | 4.5−22.7%4.2% | 5.9+37.6%3.6% | 4.3−31.5%1.8% | 6.2−21.2%1.7% | 7.9−15.5%2.6% | 9.4−11.8%3.0% | 11—3.6% | — | — | — | |
| Long-term investments | — | — | — | — | — | — | — | — | 29−35.3%16.3% | 45—25.2% | |
| Total assets | 108−34.1%100% | 164−31.6%100% | 240−32.9%100% | 358+17.3%100% | 305−2.5%100% | 313+6.1%100% | 295−13.5%100% | 341+89.2%100% | 180−0.1%100% | 180—100% | |
| Accounts payable | 4.0−21.6%3.7% | 5.1+63.5%3.1% | 3.1+12.6%1.3% | 2.8+73.0%0.8% | 1.6−64.0%0.5% | 4.5+352%1.4% | 1.0−77.3%0.3% | 4.3−23.5%1.3% | 5.7+19.2%3.1% | 4.8—2.6% | |
| Current liabilities | 92−0.2%84.9% | 92+32.8%56.1% | 69+5.4%28.9% | 66−10.6%18.4% | 74+22.4%24.1% | 60+29.9%19.2% | 46−1.2%15.7% | 47−5.2%13.7% | 49+200%27.4% | 16—9.1% | |
| Lease liabilities (non-current) | 5.7−14.4%5.3% | 6.7+141%4.1% | 2.8−54.3%1.2% | 6.1−32.0%1.7% | 9.0−20.5%2.9% | 11−14.5%3.6% | 13—4.5% | — | — | — | |
| Total liabilities | 401+14.5%370% | 350−7.0%213% | 377+0.5%157% | 375−2.6%105% | 385+46.7%126% | 263+7.1%83.9% | 245+55.2%83.1% | 158+211%46.3% | 51+180%28.2% | 18—10.1% | |
| Retained earnings | −1,759—−1623% | −1,563—−951% | −1,487—−618% | −1,344—−375% | −1,179—−386% | −1,070—−342% | −873—−296% | −674—−197% | −495—−275% | −366—−203% | |
| Shareholders' equity | −293—−270% | −186—−113% | −136—−56.6% | −17—−4.7% | −80−258%−26.1% | 51+1.6%16.1% | 50−72.8%16.9% | 183+41.5%53.7% | 129r129−20.2%71.8% | 162—89.9% | |
| Total liabilities and equity | 108−34.1%100% | 164−31.6%100% | 240−32.9%100% | 358+17.3%100% | 305−2.5%100% | 313+6.1%100% | 295−13.5%100% | 341+89.2%100% | 180−0.1%100% | 180—100% | |
| Shares outstanding | 18+118%— | 8.4r126−92.7%— | 115+1.5%— | 113+49.5%— | 76+2.5%— | 74+13.1%— | 65r65+7.5%— | 61+22.8%— | 50+18.3%— | 42—— | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | — | — | — | — | — | — | 1.0+32.5%2.4% | 0.7+3.1%2.4% | 0.7−0.6%44.4% | 0.7—466% | |
| Share-based compensation | 14−23.7%9.6% | 18−15.1%12.7% | 22−38.7%14.9% | 35+18.9%22.5% | 30+22.0%14.2% | 24+59.6%22.6% | 15−11.5%37.4% | 17−15.3%56.9% | 20−8.4%1271% | 22—14469% | |
| Cash from operating activities | −75—−51.6% | −127—−87.8% | −93—−63.5% | −150—−95.2% | −107—−51.1% | −160—−148% | −191—−467% | −159—−525% | −74—−4593% | −84—−54799% | |
| Capital expenditure | 0—0.0% | −0.1—−0.1% | 0—0.0% | −0.1—−0.1% | −0.2—−0.1% | −0.1—−0.1% | −0.2—−0.5% | −2.4—−7.8% | −0.1—−3.9% | −0.1—−45.5% | |
| Cash from investing activities | 43−54.6%29.7% | 95+1102%65.7% | 7.9—5.4% | −104−174%−66.4% | 142—67.6% | −54−168%−49.7% | 78—192% | −108−729%−355% | 17−30.4%1066% | 25—15971% | |
| Cash from financing activities | 30−27.8%20.6% | 42+3605%28.7% | 1.1−99.4%0.8% | 194+163%123% | 74−57.2%35.1% | 172+38.4%159% | 124−60.7%304% | 316+317%1042% | 76+48.0%4719% | 51—33223% | |
| Exchange-rate effect on cash | 0.0—0.0% | −0.0—−0.0% | −0.0—−0.0% | −0.5—−0.3% | −0.0−118%−0.0% | 0.3+1311%0.2% | 0.0—0.0% | −0.1−137%−0.3% | 0.2—13.1% | −0.1—−42.9% | |
| Change in cash | −1.9−120%−1.3% | 9.6—6.6% | −84—−57.3% | −61−156%−38.6% | 108—51.6% | −42−448%−38.5% | 12−75.7%29.2% | 49+155%162% | 19r19—1205% | −8.7r−8.7—−5648% | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Jun 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 | Q3 FY2023to Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | 147+6.8%100% | 33−11.9%100% | 35+16.8%100% | 34*+11.6%100% | 44+13.6%100% | 38−11.4%100% | 30−9.4%100% | 31*−9.5%100% | 39+7.7%100% | 43—100% | 33—100% | 34*—100% | 36—100% | |
| Research and development | 121−11.6%82.5% | 29−11.7%86.6% | 34−2.4%96.4% | 28*−16.9%81.2% | 31−15.5%69.3% | 33−14.6%86.4% | 35−2.3%115% | 33*−15.4%109% | 36+1.6%93.2% | 38—89.7% | 35—107% | 39*—117% | 36—98.7% | |
| Selling, general and administrative | 102−7.8%69.6% | 26−9.0%77.5% | 27−2.4%76.1% | 23*−16.2%66.8% | 27−3.7%60.4% | 28−8.3%75.1% | 27−7.4%91.1% | 27*−11.4%89.0% | 28−10.3%71.2% | 31—72.6% | 30—89.2% | 31*—90.9% | 31—85.5% | |
| Operating expenses | 229−9.3%156% | 56−10.2%167% | 62−2.3%176% | 52*−16.0%152% | 59−8.9%135% | 62−12.1%164% | 63−5.4%211% | 62*−13.6%202% | 65−3.3%168% | 71—166% | 67—202% | 72*—212% | 67—187% | |
| Operating income | −82—−56.2% | −23—−67.4% | −27—−76.3% | −18*—−52.4% | −15—−34.6% | −24—−64.3% | −33—−111% | −31*—−102% | −26—−67.8% | −28—−65.7% | −34—−102% | −38*—−112% | −31—−86.8% | |
| Interest and finance income | 2.4−51.4%1.6% | 0.7+17.8%2.2% | 0.5−48.9%1.5% | 0.6*−59.0%1.8% | 0.6−69.8%1.3% | 0.6−68.2%1.6% | 1.0−53.6%3.3% | 1.5*−41.2%4.9% | 1.8−33.4%4.7% | 1.9—4.5% | 2.2—6.5% | 2.5*—7.5% | 2.8—7.6% | |
| Interest expense and finance costs | 49+10.1%33.6% | 13+17.1%39.3% | 13+14.2%35.8% | 13*+12.6%37.0% | 11−3.3%25.0% | 11+25.5%29.6% | 11+86.8%36.6% | 11*+80.5%36.7% | 11+87.5%29.4% | 8.9—20.9% | 5.9—17.8% | 6.2*—18.4% | 6.1—16.9% | |
| Other non-operating income (expense) | −142—−97.1% | −44—−133% | 4.4−55.6%12.5% | −84*−21636%−248% | −18—−40.6% | −13−125%−33.8% | 9.8—32.8% | 0.4*—1.3% | −5.8—−14.9% | 52—121% | −3.5—−10.7% | −3.9*—−11.6% | −3.2—−9.0% | |
| Income before tax | −225—−153% | −67—−200% | −22—−63.9% | −102*—−300% | −33—−75.1% | −37−256%−98.1% | −23—−78.0% | −31*—−101% | −32—−82.6% | 24—55.8% | −37—−113% | −42*—−124% | −34—−95.8% | |
| Income tax | −0.0—−0.0% | 0−100%0.0% | 0.0−97.2%0.0% | −0.1*—−0.2% | 0.0+21.4%0.1% | 0.0−40.3%0.1% | 0.0−49.3%0.1% | −0.1*−184%−0.4% | 0.0+133%0.1% | 0.1—0.2% | 0.1—0.2% | 0.1*—0.4% | 0.0—0.0% | |
| Net income including minority interests | −225—−153% | −67*—−200% | −22—−63.9% | −102*—−300% | −33*—−75.2% | −37*−257%−98.2% | −23—−78.2% | −31*—−101% | −32*—−82.7% | 24*—55.6% | −37—−113% | −42*—−124% | −35*—−95.8% | |
| Net income attributable to shareholders | −225—−153% | −67—−200% | −22—−63.9% | −102*—−300% | −33—−75.2% | −37−257%−98.2% | −23—−78.2% | −31*—−101% | −32—−82.7% | 24—55.6% | −37—−113% | −42*—−124% | −35—−95.8% | |
| Earnings per share, basic | — | -2.32—— | -1.02—— | — | -3.82—— | -4.32−291%— | -2.77—— | — | -3.85r-0.26—— | 2.26r0.15—— | -4.85r-0.32—— | — | -0.30—— | |
| Earnings per share, diluted | — | -2.32—— | -1.24—— | — | -3.82—— | -4.32—— | -2.77—— | — | -3.85r-0.26—— | -2.97r-0.20—— | -4.85r-0.32—— | — | -0.30—— | |
| Shares, weighted average (basic) | 0.0+236%— | 0.0+236%— | 0.0+160%— | — | 0.0+4.0%— | 0.0+6.8%— | 0.0+10.0%— | — | 0.0r0.1−92.7%— | 0.0r121—— | 0.0r115—— | — | 0.1r114—— | |
| Shares, weighted average (diluted) | 0.0+236%— | 0.0+236%— | 0.0+192%— | — | 0.0+4.0%— | 0.0−16.3%— | 0.0+10.0%— | — | 0.0r0.1−92.7%— | 0.0r154—— | 0.0r115—— | — | 0.1r114—— | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 55—49.4% | 55+42.0%49.4% | 91+134%69.1% | 61−3.1%55.8% | 38−48.3%39.1% | 39−54.3%36.9% | 39+26.6%30.4% | 62+19.6%38.0% | 73+66.8%38.4% | 85—39.6% | 31—15.0% | 52r52—21.7% | 44—16.2% | |
| Short-term investments | 10—9.1% | 10−21.9%9.1% | 0−100%0.0% | 3.2−93.1%3.0% | 8.2−86.5%8.5% | 13−80.7%12.4% | 31−73.6%24.4% | 46−66.8%28.1% | 61−63.1%32.0% | 67—31.5% | 118—57.7% | 139—57.9% | 165—61.0% | |
| Receivables | 30—26.8% | 30−9.3%26.8% | 23−33.7%17.8% | 26−14.9%24.1% | 32+0.3%33.1% | 33−13.3%31.4% | 35+13.4%27.6% | 31+14.1%18.7% | 32−16.2%16.8% | 38—17.8% | 31—15.2% | 27—11.2% | 38—14.0% | |
| Inventory | 4.0—3.6% | 4.0−20.0%3.6% | 3.6−24.5%2.7% | 4.0−14.8%3.7% | 4.0−15.1%4.1% | 5.0+43.6%4.8% | 4.8+72.2%3.7% | 4.7+55.7%2.9% | 4.7+50.5%2.5% | 3.5—1.6% | 2.8—1.4% | 3.0—1.3% | 3.1—1.2% | |
| Other current assets | 7.4—6.7% | 7.4−10.2%6.7% | 8.5−17.1%6.5% | 9.2−25.0%8.5% | 8.0−45.6%8.3% | 8.2−44.7%7.9% | 10−33.6%8.1% | 12+3.7%7.4% | 15+10.6%7.8% | 15—7.0% | 15—7.6% | 12—4.9% | 13—4.9% | |
| Current assets | 106—95.6% | 106+8.7%95.6% | 126+5.1%96.1% | 103−34.1%95.1% | 90−51.4%93.3% | 98−53.1%93.3% | 120−39.4%94.1% | 156r156−33.1%95.2% | 185−29.8%97.5% | 209—97.5% | 198—97.0% | 234—97.3% | 263—97.5% | |
| Property, plant and equipment | 0.1—0.1% | 0.1−61.5%0.1% | 0.1−71.7%0.1% | 0.1−74.0%0.1% | 0.1−75.4%0.1% | 0.2−61.1%0.2% | 0.3−55.2%0.3% | 0.4−34.0%0.2% | 0.5−27.8%0.3% | 0.6—0.3% | 0.7—0.4% | 0.6—0.3% | 0.7—0.3% | |
| Right-of-use (leased) assets | 4.3—3.8% | 4.3−16.2%3.8% | 4.4−19.5%3.4% | 4.5−22.7%4.2% | 4.7+81.0%4.9% | 5.1+60.2%4.8% | 5.5+46.6%4.3% | 5.9+37.6%3.6% | 2.6−46.1%1.4% | 3.2—1.5% | 3.7—1.8% | 4.3—1.8% | 4.8—1.8% | |
| Total assets | 111—100% | 111+6.1%100% | 131+2.9%100% | 108−34.1%100% | 96−49.2%100% | 105−51.0%100% | 128−37.5%100% | 164−31.6%100% | 189−29.8%100% | 214—100% | 204—100% | 240—100% | 270—100% | |
| Accounts payable | 7.7—6.9% | 7.7+195%6.9% | 4.3−27.1%3.3% | 4.0−21.6%3.7% | 5.4−6.8%5.6% | 2.6−7.2%2.5% | 5.9+16.8%4.6% | 5.1+63.5%3.1% | 5.8+513%3.1% | 2.8—1.3% | 5.0—2.5% | 3.1—1.3% | 0.9—0.3% | |
| Current liabilities | 134—121% | 134+35.3%121% | 117+29.8%89.3% | 92−0.2%84.9% | 87+41.7%90.6% | 99+72.2%94.6% | 90+38.3%70.8% | 92+32.8%56.1% | 61−0.9%32.5% | 58—26.9% | 65—32.0% | 69—28.9% | 62—23.0% | |
| Lease liabilities (non-current) | 5.2—4.7% | 5.2−17.1%4.7% | 5.5−15.7%4.2% | 5.7−14.4%5.3% | 6.0—6.2% | 6.3+555%6.0% | 6.5+244%5.1% | 6.7+141%4.1% | 0−100%0.0% | 1.0—0.4% | 1.9—0.9% | 2.8—1.2% | 3.7—1.4% | |
| Total liabilities | 441—397% | 441+28.4%397% | 397+19.0%302% | 401+14.5%370% | 365+4.7%380% | 344−0.7%328% | 334−10.7%261% | 350−7.0%213% | 349−5.7%184% | 346—162% | 373—183% | 377—157% | 370—137% | |
| Retained earnings | −1,849—−1661% | −1,849—−1661% | −1,782—−1356% | −1,759—−1623% | −1,657—−1722% | −1,624—−1549% | −1,587—−1243% | −1,563—−951% | −1,533—−809% | −1,501—−701% | −1,524—−746% | −1,487—−618% | −1,445—−535% | |
| Shareholders' equity | −330—−297% | −330—−297% | −266—−202% | −293—−270% | −269—−280% | −239—−228% | −206—−161% | −186—−113% | −160—−84.3% | −132—−61.8% | −169—−82.6% | −136—−56.6% | −100—−37.2% | |
| Total liabilities and equity | 111—100% | 111+6.1%100% | 131+2.9%100% | 108−34.1%100% | 96−49.2%100% | 105−51.0%100% | 128−37.5%100% | 164−31.6%100% | 189−29.8%100% | 214—100% | 204—100% | 240—100% | 270—100% | |
| Shares outstanding | 23—— | 23+162%— | 23+163%— | 18+118%— | 8.7−93.1%— | 8.6−93.1%— | 8.6−92.6%— | 8.4r126−92.7%— | 125+9.4%— | 125—— | 116—— | 115—— | 115—— | |
| Cash-flow statement | ||||||||||||||
| Share-based compensation | 12−24.4%7.9% | 1.9−49.0%5.8% | 3.0−15.5%8.6% | 3.9*+1.0%11.5% | 2.8−33.0%6.4% | 3.8−30.1%10.0% | 3.6r3.6−28.4%11.9% | 3.9*−25.4%12.7% | 4.2−17.6%10.8% | 5.4—12.6% | 5.0—15.0% | 5.2*—15.4% | 5.1—14.1% | |
| Cash from operating activities | −65—−44.6% | −25*—−74.6% | −23—−64.8% | −12*—−34.7% | −5.9*—−13.3% | −19*—−49.3% | −39—−130% | −26*—−84.5% | −19*—−50.2% | −38*—−90.0% | −44—−132% | −19*—−55.1% | −30*—−82.0% | |
| Capital expenditure | — | — | — | 0*—0.0% | 0*—0.0% | 0*—0.0% | 0—0.0% | — | 0*—0.0% | 0*—0.0% | −0.2—−0.6% | 0*—0.0% | 0*—0.0% | |
| Cash from investing activities | 3.0−94.7%2.0% | −10*−155%−30.0% | 3.2−79.1%9.1% | 5.0*−66.2%14.7% | 4.8*−35.7%10.9% | 18*−64.3%48.2% | 15−30.3%50.9% | 15*−44.9%48.4% | 7.5*—19.3% | 51*—120% | 22—66.2% | 27*—79.5% | −7.7*—−21.3% | |
| Shares issued | — | 0*—0.0% | 20—57.7% | — | — | 0*—0.0% | 0—0.0% | — | — | — | — | — | — | |
| Cash from financing activities | 79+7486%53.6% | −0.9*−352%−2.7% | 50—142% | 30*+4266%87.1% | 0*—0.0% | 0.4*—0.9% | 0—0.0% | 0.7*+158%2.2% | 0*—0.0% | — | — | 0.3*—0.8% | 0*—0.0% | |
| Exchange-rate effect on cash | 0.0−82.8%0.0% | −0.0*−150%−0.0% | 0.0−60.0%0.0% | 0.0*—0.0% | 0.0*−94.4%0.0% | 0.0*—0.0% | 0.0—0.0% | −0.0*−122%−0.1% | 0.0*—0.1% | −0.0*—−0.0% | −0.0—−0.0% | 0.1*—0.3% | −0.1*—−0.1% | |
| Change in cash | 16—11.1% | −36*—−107% | 30—86.3% | 23*—67.1% | −1.1*—−2.4% | −0.0*−100%−0.1% | −24—−78.9% | −10*−220%−33.9% | −12*—−30.8% | 54*—126% | −22—−65.8% | 8.6*—25.5% | −37*—−103% | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Jun 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
What Karyopharm Therapeutics Inc. sells: revenue by product line, fiscal 2025#
As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.
Products and services
- Product(total)$115 M79%+1.8%
- License and Other Revenue$31 M21%-3.8%
Source: SEC annual report (XBRL data) · as of Dec 31, 2025
Where Karyopharm Therapeutics Inc. operates: 3 countries#
Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue. 2 subsidiaries on file.
| Country | Presence | Revenue there |
|---|---|---|
| 🇺🇸 USA | Headquarters1 office | — |
| 🇩🇪 Germany | 1 subsidiary | — |
| 🇮🇱 Israel | 1 subsidiary | — |
Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided
Executive pay at Karyopharm Therapeutics Inc.#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2025Mr. Paulson | $2.3 M | $2.1 M | $1.7 M | $14 |
| 2024Mr. Paulson | $2.1 M | $1.7 M | $1.1 M | $20 |
| 2023Mr. Paulson | $2.6 M | $36 K | $1.2 M | $25 |
Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025
Events at Karyopharm Therapeutics Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Warning signs in the last three years
Bankruptcy or receivership 1 · Delisting notice 1 · Debt called early 2 · Directors and officers 6 · Material agreement 6 · New debt 3 · Unregistered share sale 3 · Shareholder rights changed 2 · Bylaws or fiscal year changed 2 · Shareholder vote 3 · Results announced 9
| Filed | What happened | Filing |
|---|---|---|
| Delisting notice | 8-K | |
| Bankruptcy or receivershipDebt called earlyMaterial agreementNew debt | 8-K | |
| Shareholder rights changedBylaws or fiscal year changed | 8-K | |
| Debt called earlyMaterial agreementUnregistered share sale | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Directors and officersShareholder vote | 8-K | |
| Results announced | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Material agreement | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Material agreementNew debt | 8-K | |
| Directors and officersMaterial agreementNew debtUnregistered share saleResults announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Directors and officersShareholder vote | 8-K | |
| Results announced | 8-K | |
| Shareholder rights changedBylaws or fiscal year changed | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 5, 2026
Acquisitions and funding#
2 private funding rounds before listing
Private share sales · funding history
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
Lobbying by Karyopharm Therapeutics Inc.#
$100 K spent on lobbying the US Congress and federal agencies in 2025, most often on health issues.
- Health Issues1 report
Lobbying firms hired in 2025
Sidley Austin LLP $100 K
| Year | Spending | Own lobbyists | Reports |
|---|---|---|---|
| 2026 (so far) | $0 | — | 3 |
| 2025 | $100 K | — | 1 |
| 2019 | $220 K | — | 4 |
| 2018 | $60 K | — | 1 |
Source: Lobbying Disclosure Act reports (Form LD-2). Filed as “Karyopharm Therapeutics Inc.,” and “Karyopharm Therapeutics”. Reports round to the nearest $10,000, and one of less than $5,000 counts as zero
H-1B hiring at Karyopharm Therapeutics Inc.#
4 labor condition applications certified in fiscal 2026 for 4 positions, at a median wage of $189 K a year.
| Job title | Positions | Median wage offered |
|---|---|---|
| Senior Manager, Regulatory OperationsRegulatory Affairs Managers | 2 | $189 K |
| Associate Director, Regulatory OperationsRegulatory Affairs Managers | 1 | $189 K |
| Sr Scientist, Analytical ChemistryChemists | 1 | $153 K |
Where: Newton, MA 4
| Fiscal year | Certified | Positions | Median wage | Filed |
|---|---|---|---|---|
| FY2026 | 4 | 4 | $189 K | 4 |
| FY2025 | 8 | 8 | $133 K | 8 |
| FY2024 | 2 | 2 | $125 K | 2 |
| FY2023 | 13 | 13 | $130 K | 13 |
| FY2022 | 11 | 11 | $140 K | 11 |
| FY2021 | 5 | 5 | $123 K | 6 |
| FY2020 | 13 | 13 | $120 K | 13 |
Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Karyopharm Therapeutics Inc.
FDA drug approvals: Karyopharm Therapeutics Inc.#
1 approved applications held, 1 of them new molecular entities; 0 approvals and 2 new uses in 2020.
| Approved | Drug | Kind |
|---|---|---|
| 2026-04-23 | Xpovionew useSelinexor · NDA212306 (SUPPL-18) | New drug (NDA) |
| 2020-12-18 | Xpovionew useSelinexor · NDA212306 (SUPPL-5) | New drug (NDA) |
| 2020-06-22 | Xpovionew useSelinexor · NDA212306 (SUPPL-1) | New drug (NDA) |
| 2019-07-03 | Xpovionew moleculeSelinexor · NDA212306 | New drug (NDA) |
Source: Drugs@FDA (openFDA). Approvals are listed under the application's current holder (KARYOPHARM THERAPS), so they follow acquisitions
How Karyopharm Therapeutics Inc. compares in Biotechnology
- Market cap$20 M · higher than 17% of 726
- Revenue$146 M · higher than 73% of 647
- Net margin-153.3% · higher than 35% of 408
- Revenue growth0.6% · higher than 46% of 438
- Price / sales0.1× · lower than 99% of 339
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Karyopharm Therapeutics Inc.🇺🇸 | $20 M | — | -153.3% | +0.6% |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
Sources and freshness
- Market cap:
- Oct 30, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As on 2021
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, GLEIF register; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Karyopharm Therapeutics Inc.? Verify and update this profile — free
Show Karyopharm Therapeutics Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.